Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Beam Therapeutics ( (BEAM) ).
On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% stake. Beam’s shares were converted into $255.1 million in cash, with potential for additional consideration, impacting its financial outlook ahead of the 2026 J.P. Morgan Healthcare Conference.
The most recent analyst rating on (BEAM) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
Beam Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and negative cash flows. The technical analysis provides some short-term bullish signals, but the valuation remains unattractive due to a negative P/E ratio and lack of dividends. The absence of earnings call and corporate events data limits additional insights into the company’s future prospects.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
Average Trading Volume: 2,370,919
Technical Sentiment Signal: Buy
Current Market Cap: $2.69B
For an in-depth examination of BEAM stock, go to TipRanks’ Overview page.